Soy isoflavone genistein in prevention and treatment of prostate cancer

Perabo, Frank; Löw, E C Von; Ellinger, Jörg; Rücker, Alexander von; Müller, Stefan; Bastian, Patrick J.

doi:10.1038/sj.pcan.4501000

Cited by 115 publications

(82 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our studies, the percentage of MHCC97-H cells undergoing apoptosis was significantly higher in the genistein group than in the control group. This finding is consistent with apoptosis studies in breast, prostate and gastric cancer cell lines treated with genistein [21,22] . The adhesion and invasiveness of tumor cells represents one of the several important steps necessary for the formation of metastases.…”

Section: Discussionsupporting

confidence: 81%

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma

Gu¹,

Zhu²,

Dai³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the inhibitory effects of genistein on metastasis of MHCC97-H hepatocellular carcinoma cells and to explore the underlying mechanism. METHODS:MHCC97-H hepatocellular carcinoma cells were exposed to genistein. A cell attachment assay was carried out in a microculture well pre-coated with fibronectin. The invasive activity of tumor cells was assayed in a transwell cell culture chamber, and cell cycle and apoptosis were evaluated by a functional assay. In addition, the expression and phosphorylation of FAK were detected by Western blotting. In situ xenograft transplantation of hepatocellular carcinoma was performed in 12 nude mice and lung metastasis of hepatocellular carcinoma was observed. RESULTS:Genistein significantly inhibited the growth of MHCC97-H cells in vitro . Adhesion and invasiveness of MHCC97-H cells were inhibited in a concentrationdependent fashion, and the inhibitory effect of genistein was more potent in the 10 μg/mL and 20 μg/ mL genistein-treated groups. Genistein caused G0/G1 cell cycle arrest, an S phase decrease, and increased apoptosis. The expression and phosphorylation of FAK in MHCC-97H cells were significantly decreased. In situ xenograft transplantation of hepatocellular carcinoma was also significantly suppressed by genistein. The number of pulmonary micrometastatic foci in the genistein group was significantly lower compared with the control group (12.3 ± 1.8 vs 16.6 ± 2.6, P < 0.05).CONCLUSION: Genistein appears to be a promising agent in the inhibition of metastasis of hepatocellular carcinoma.

show abstract

Section: Discussionsupporting

confidence: 81%

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma

Gu¹,

Zhu²,

Dai³

et al. 2009

WJG

View full text Add to dashboard Cite

show abstract

“…The severity of the disease and its clinical heterogeneity, combined with the lack of effective diagnostic markers and therapeutic strategies, make the treatment of PCa a major challenge (26,27). Therefore, it is urgent to screen key genes that are associated with the metastasis of PCa with the aim of improving its treatment.…”

Section: Discussionmentioning

confidence: 99%

Identification of candidate genes that may contribute to the metastasis of prostate cancer by bioinformatics analysis

et al. 2017

View full text Add to dashboard Cite

Abstract. To screen for marker genes associated with to the metastasis of prostate cancer (PCa), in silico analysis of the Gene Expression Omnibus dataset GSE27616, which included 4 metastatic and 5 localized PCa tissue samples, was performed. Differentially expressed genes (DEGs) were identified. Their potential functions were identified by Gene Ontology and Kyoto Encyclopedia of Gene Genomes pathway enrichment analyses. Furthermore, protein-protein interaction (PPI) networks for DEGs were constructed using Cytoscape. Module analysis of the PPI networks was performed with Cluster ONE. A total of 561 DEGs were screened, including 208 upregulated and 353 downregulated genes. Proliferating cell nuclear antigen (PCNA) and cluster of differentiation 4 (CD4) exhibited the highest degrees of connectivity in the PPI networks for up-and down-regulated DEGs, respectively. The DEGs in module A, including CD58, 2, 4 and major histocompatibility complex, class II DP-β1 were enriched in 'cell adhesion molecules'. Anaphase promoting complex subunit 4, cell division cycle 20 and cell division cycle 16 in module B were primarily enriched in 'cell cycle'. The DEGs, including CD4, PCNA and baculoviral IAP repeat containing 5, may have critical roles in PCa metastasis and could thus be used as novel biomarker candidates for metastatic PCa. However, further studies are required to verify these results.

show abstract

“…Genistein, one of the principal soy isoflavones, exhibits a wide array of chemopreventive actions due to its antiestrogenic activities (8,9). Structurally, genistein resembles the biphenolic 17h-estradiol and hence displays differential binding affinities to the two estrogen receptors (ER), ERa and ERh, with 20-to 30-fold stronger binding to ERh (10).…”

Section: Introductionmentioning

confidence: 99%

Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

Basak

Pookot

Noonan

et al. 2008

Molecular Cancer Therapeutics

117

View full text Add to dashboard Cite

Androgen receptor (AR) is a ligand-activated transcription factor belonging to the steroid hormone receptor family and is very important for the development and progression of prostate cancer. The soy isoflavone genistein has been shown previously to down-regulate AR in androgendependent prostate cancer cell lines such as LNCaP. However, the mechanism(s) by which AR is downregulated by genistein is still not known fully. We show a new mechanism by which genistein inhibits AR protein levels. We show that genistein-treated LNCaP cells exhibit increased ubiquitination of AR, suggesting that AR protein is down-regulated via a proteasome-mediated pathway. AR is normally stabilized by the chaperone activity of the heat shock protein Hsp90. The increased ubiquitination of AR after genistein treatment is attributed to decreased Hsp90 chaperone activity as assessed by its increased functionally inactive acetylated form. Consistent with this result, we find that HDAC6, which is a Hsp90 deacetylase, is inhibited by the antiestrogenic activity of genistein. Hence, in this study, we elucidate a novel mechanism of AR down-regulation by genistein through inhibition of HDAC6-Hsp90 cochaperone function required to stabilize AR protein. Our results suggest that genistein could be used as a potential chemopreventive agent for prostate cancers along with known inhibitors of HDAC6 and

show abstract

Soy isoflavone genistein in prevention and treatment of prostate cancer

Cited by 115 publications

References 64 publications

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma

Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma

Identification of candidate genes that may contribute to the metastasis of prostate cancer by bioinformatics analysis

Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

Contact Info

Product

Resources

About